TREATMENT HUMAN BONE

Brand Owner (click to sort) Address Description
ADVANCING OSTEOBIOLOGIC SCIENCES OSTEOTECH, INC. 51 James Way SHREWSBURY NJ 07724 Treatment of human bone for surgical implants;OSTEOBIOLOGIC SCIENCES;
ASSURE DCI Donor Services, Inc. Suite 300 1600 Hayes Street Nashville TN 372033034 treatment of human bone and tissue for surgical implants;treating and processing bone and tissue, namely, cleaning and disinfecting of human bone and tissue for surgical implants; cleaning and disinfecting human bone and tissue samples; cleaning and disinfection of allograft bone and tissue samples; treating and processing of human bone and tissue to be used for implantation, namely, cleaning and disinfecting human bone and tissue samples;
ASSURE ST DCI Donor Services, Inc. Suite 300 1600 Hayes Street Nashville TN 372033034 treatment of human bone and tissue for surgical implants;treating and processing bone and tissue, namely, cleaning, disinfecting, and sterilizing of human bone and tissue for surgical implants; cleaning and disinfecting human bone and tissue samples; cleaning and disinfection of allograft bone and tissue samples; treating and processing of human bone and tissue to be used for implantation, namely, cleaning, disinfecting, and sterlizing human bone and tissue samples;
OSTEOACTIVE OSTEOTECH, INC. 51 James Way SHREWSBURY NJ 07724 TREATMENT OF HUMAN BONE FOR SURGICAL IMPLANTS;
TRABECULARPLASTY Cole, Brian 1408 Wood Iris Lane Lawrenceville GA 30045 Treatment of human bone for surgical implants;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.